Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Mizuho analyst Anthony Petrone maintains Staar Surgical (NASDAQ:STAA) with a Buy and raises the price target from $45 to $53.
Canaccord Genuity analyst Jon Young maintains Staar Surgical (NASDAQ:STAA) with a Hold and raises the price target from $32 ...
STAAR Surgical reports Q1 2024 net sales surpassing $77 million, with U.S. ICL sales hitting $5 million, the highest since FDA ...
Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong prelimi...
Needham analyst David Saxon reiterates Staar Surgical (NASDAQ:STAA) with a Hold.
TVGN: 101% | Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development CADL: 62% | Candel Ther...
U.S. ICL sales expected to be $5 million for the quarter. This represents the Company's highest quarterly ICL sales in the ...
